Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2022 - 2025)

Corvus Pharmaceuticals has reported Return on Capital Employed over the past 4 years, most recently at 0.51% for Q3 2025.

  • Quarterly results put Return on Capital Employed at 0.51% for Q3 2025, up 114.0% from a year ago — trailing twelve months through Sep 2025 was 0.51% (up 114.0% YoY), and the annual figure for FY2024 was 1.26%, down 79.0%.
  • Return on Capital Employed for Q3 2025 was 0.51% at Corvus Pharmaceuticals, up from 0.54% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CRVS hit a ceiling of 0.49% in Q3 2023 and a floor of 1.64% in Q3 2024.
  • Median Return on Capital Employed over the past 4 years was 0.57% (2023), compared with a mean of 0.68%.
  • Biggest five-year swings in Return on Capital Employed: plummeted -115bps in 2024 and later surged 114bps in 2025.
  • Corvus Pharmaceuticals' Return on Capital Employed stood at 0.51% in 2022, then fell by -9bps to 0.56% in 2023, then plummeted by -73bps to 0.97% in 2024, then skyrocketed by 48bps to 0.51% in 2025.
  • The last three reported values for Return on Capital Employed were 0.51% (Q3 2025), 0.54% (Q2 2025), and 0.57% (Q1 2025) per Business Quant data.